amifostine anhydrous has been researched along with Leukopenia in 11 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Leukopenia: A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).
| Excerpt | Relevance | Reference |
|---|---|---|
| " In Europe fotemustine (Muphoran) is widely used in the treatment of brain metastases in melanoma patients." | 9.08 | Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study. ( Breitbart, E; Makki, A; Mohr, P; Schadendorf, D, 1998) |
| " In Europe fotemustine (Muphoran) is widely used in the treatment of brain metastases in melanoma patients." | 5.08 | Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study. ( Breitbart, E; Makki, A; Mohr, P; Schadendorf, D, 1998) |
| " We conclude that WR-2721 is a potentially toxic compound that produces no amelioration of cyclophosphamide toxicity in the doses used." | 2.65 | Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide. ( Ayoob, MJ; Dritschilo, A; Smith, FP; Woolley, PV, 1983) |
| " injection of 200 mg/kg WR-2721 at 5 min prior to the administration of this combination enabled us to increase the CBDCA dose from a nontoxic level of 45 mg/kg to a normally toxic dose of 60 mg/kg in non-tumor-bearing BALB/c mice while maintaining the 5FU dose at 100 mg/kg." | 1.28 | Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil. ( Peters, GJ; Treskes, M; van der Vijgh, WJ; van der Wilt, CL; van Laar, JA, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (36.36) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gómez, HL | 1 |
| Samanéz, C | 1 |
| Campana, F | 1 |
| Neciosup, SP | 1 |
| Vera, L | 1 |
| Casanova, L | 1 |
| Leon, J | 1 |
| Flores, C | 1 |
| de Mendoza, FH | 1 |
| Casteñeda, CA | 1 |
| Pinto, JA | 1 |
| Vallejos, CS | 1 |
| Glick, JH | 2 |
| Glover, D | 2 |
| Weiler, C | 2 |
| Norfleet, L | 1 |
| Yuhas, J | 1 |
| Kligerman, MM | 2 |
| McNally, NJ | 1 |
| Woolley, PV | 1 |
| Ayoob, MJ | 1 |
| Smith, FP | 1 |
| Dritschilo, A | 1 |
| Green, D | 1 |
| Bensely, D | 1 |
| Schein, P | 1 |
| Mohr, P | 1 |
| Makki, A | 1 |
| Breitbart, E | 1 |
| Schadendorf, D | 1 |
| Büntzel, J | 1 |
| Glatzel, M | 1 |
| Schuth, J | 1 |
| Weinaug, R | 1 |
| Küttner, K | 1 |
| Fröhlich, D | 1 |
| Guest, I | 1 |
| Uetrecht, J | 1 |
| van der Wilt, CL | 2 |
| van Laar, JA | 2 |
| Gyergyay, F | 1 |
| Smid, K | 1 |
| Peters, GJ | 2 |
| Treskes, M | 1 |
| van der Vijgh, WJ | 1 |
| Hurowitz, S | 1 |
1 review available for amifostine anhydrous and Leukopenia
| Article | Year |
|---|---|
Bone marrow stem cell protection from chemotherapy by low--molecular-weight compounds.
Topics: Amifostine; Anemia, Aplastic; Antineoplastic Agents; Bone Marrow Cells; Ethylenes; Growth Inhibitors | 2001 |
3 trials available for amifostine anhydrous and Leukopenia
| Article | Year |
|---|---|
Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival.
Topics: Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamid | 2012 |
Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide.
Topics: Adult; Aged; Amifostine; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Drug Interactions; | 1983 |
Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study.
Topics: Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brai | 1998 |
7 other studies available for amifostine anhydrous and Leukopenia
| Article | Year |
|---|---|
Phase I controlled trials of WR-2721 and cyclophosphamide.
Topics: Adult; Aged; Agranulocytosis; Amifostine; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combinati | 1984 |
The effect of misonidazole combined with WR2721 on tumour response and leucopenia due to cyclophosphamide or melphalan.
Topics: Amifostine; Animals; Cell Survival; Cyclophosphamide; Drug Therapy, Combination; Leukopenia; Melphal | 1982 |
Preclinical evaluation of WR-151327: an orally active chemotherapy protector.
Topics: Administration, Oral; Amifostine; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Bo | 1994 |
[Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma].
Topics: Adult; Aged; Amifostine; Anemia; Antineoplastic Agents; Brachytherapy; Carboplatin; Combined Modalit | 1999 |
Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice.
Topics: Amifostine; Animals; Cisplatin; Colonic Neoplasms; Female; Fluorouracil; Leukopenia; Mice; Mice, Inb | 1992 |
Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil.
Topics: Amifostine; Anemia; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Ne | 1992 |
WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial.
Topics: Aged; Amifostine; Cyclophosphamide; Drug Evaluation; Humans; Leukopenia; Middle Aged; Neoplasms; Org | 1986 |